Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
Previous guidelines for the treatment of people with type 2 diabetes mellitus (T2D) have relied heavily upon rigid algorithms for the sequential addition of pharmacotherapies to achieve target glycemic control. More recent guidelines advocate a personalized approach for diabetes treatment, to improve patient satisfaction, quality of life, medication adherence and overall health outcomes. Clinicians should work with patients to develop personalized goals for their treatment, including targeted glycemic control, weight management, prevention and treatment of associated comorbidities and avoidance of complications such as hypoglycemia. Factors that affect the intensity of treatment and choice of pharmacotherapy should include medical and patient influences. Medical considerations include the diabetes phenotype, biomarkers including genetic tests, and the presence of comorbidities such as cardiovascular, renal, or hepatic disease. Patient factors include their treatment preference, age and life expectancy, diabetes duration, hypoglycemia fear and unawareness, psychological and social circumstances. The use of a personalized approach in the management of people with T2D can reduce the cost and failure associated with the algorithmic "one-size-fits-all" approach, to anticipate disease progression, improve the response to diabetes pharmacotherapy and reduce the incidence of diabetes-associated complications. Ultimately, the use of personalized medicine in people with T2D should improve medication adherence, patient satisfaction and quality of life to reduce diabetes distress and improve physical health outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Their use in people with T2D can support an additional weight loss of 2 to 4kg.76 Metformin use is considered at least weight neutral though may be associated with a modest weight loss, as observed in the Diabetes Prevention Program.81 The use of DPP-IV inhibitors in people with T2D is considered weight neutral.82 The…”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“9kg in people with T2D.(51) In a dedicated weight loss trial of overweight and obese patients (with or without T2D), semaglutide 2.”
BackgroundDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cited by
Items 101–176 of 176
Our National Approach to Diabetes
Califf, R. M. (2023) · Diabetes Care · doi:10.2337/dci22-0054 · Cited by 1
Primary Care Medicine - Theory and Practice
Çakmur, H. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.111122 · Cited by 1
Como tratar a obesidade associada à diabetes tipo 2?
Proença, C., Rufino, A. T., Freitas, M., Fernandes, E., LAQV, R. L. D. F., & LAQV, R. L. D. F. (2024) · Revista de Ciência Elementar · doi:10.24927/rce2024.006 · Cited by 1
Transforming diabetes care: Latest advancements in treatment and technology
Choudhary, S., Gaikwad, S., & Jadhav, S. (2024) · International Journal of Pharmacy and Pharmaceutical Science · doi:10.33545/26647222.2024.v6.i1b.105 · Cited by 1
Alharbi, A. E., Ahmad, M. S., Damanhouri, Z. A., Mosli, H. H., Yaghmour, K. A., Refai, F. A., Issa, N. M., & Alkreathy, H. M. (2024) · Gene · doi:10.1016/j.gene.2024.148648 · Cited by 1
Alfaraj, S., Vos, R. C., Spruit, M. R., Groenwold, R. H. H., & Mook-Kanamori, D. O. (2025) · British Journal of General Practice · doi:10.3399/bjgp.2024.0693 · Cited by 1
Jouabadi, S. M., Ahluwalia, T. S., Muka, T., & Ahmadizar, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.917977 · Cited by 1
Thomsen, C. H. N. (2024) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau763298432 · Cited by 1
Williams, D. M., & Stephens, J. W. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s363555
Self-citationZhu, L., & Zhou, Q. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s362431
Aberra, Y. T., Ma, L., Björkegren, J., & Civelek, M. (2023) · eLife · doi:10.7554/elife.79834.sa2
Lee, S.-Y., Hayes, L., Ozaydin, B., Howard, S. W., Garretson, A., Bradley, H., Land, A. M., Delaney, E. W., Pritchett, A., Furr, A. L., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3143007/v1
A Patient-Centered Management of Patients with Diabetes Type 2: Are All Diabetic Patients the Same?
Bosnić, Z., Šojat, D., Kurevija, T., Pirić, M., Božinović, R., Miletić, M., Feldi, I., Bačun, T., Žagar, S., & Majnarić, L. T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003106
Zengul, A. G., Evans, E., & Thirumalai, M. (2023) · doi:10.2196/preprints.55512
Type 2 Diabetes Mellitus Reversibility in African American Adults
Gambhir, K. K. (2023) · Endocrinology and Disorders · doi:10.31579/2640-1045/129
Gutierrez-Martinez, I., Ramos-Rodriguez, A., Diaz-Perez, E., Ordoñez-Jarillo, J., Matehuala-Morán, I., & Alfaro-Ponce, M. (2023) · IEEE EMBS R9 Conference · doi:10.1109/ieeeconf60929.2023.10525616
SCIENCE OF THE 21ST CENTURY: SEARCHES, PROBLEMS, DEVELOPMENT PROSPECTS
International Science Group, & Vladlenov, D. (2024) · doi:10.46299/isg.p.2024.1.27
Etiopatogenia y situación epidemiológica de la diabetes mellitus tipo 1
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.001
Bioinformatics in Personalized Medicine: Tools and Techniques for Modern Healthcare
Farhan, Z. R., Nafil, H. A., Kareem, R. W. A.-D., & Araibi, Z. K. A. (2024) · Bright Sky Publications eBooks · doi:10.62906/bs.book.188
Demidova, T. Y., & Омариевна, У. Ф. (2024) · FOCUS Endocrinology · doi:10.62751/2713-0177-2024-5-3-03
Healey, E., & Kohane, I. S. (2024) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc53108.2024.10781685
Jaya, I. P. K., Wibawa, I. K., & Mahadewa, T. G. B. (2024) · International Journal Of Scientific Advances · doi:10.51542/ijscia.v5i6.27
PREVALANCE OF PHARMACOEPIDEMIOLOGICAL STUDIES OF DIABETES MELLITUS IN SOUTHERN PART OF INDIA
(2024) · International Journal of Biology Pharmacy and Allied Sciences · doi:10.31032/ijbpas/2025/14.1.9797
李, 康. (2024) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2024.34367
Key determinants of blood sugar control in reproductive-age women with type 2 diabetes in Indonesia
Yonifa, F. P., Subrata, S. A., & Kamal, S. (2024) · Innovation in Health for Society · doi:10.31603/ihs.11280
Jeter, A. F., Melton, B. L., & Newell, B. J. (2025) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2025.97
Ismael, L. H. Y., Tarish, B. S. A., Nasir, W. S. K., Kadr, Z. M. S., & Kazim, E. W. J. (2025) · Bright Sky Publications eBooks · doi:10.62906/bs.book.305
Khan, W. R. A., Kumar, V., & Mehetre, J. (2025) · International Journal of Pharmacognosy and Clinical Research · doi:10.33545/2664763x.2025.v7.i1a.55
Chen, X., Meng, Y., Chen, B., Zhang, L., Liu, Z., Shi, M., Zhang, B., García, C., & Sareh, P. (2025) · doi:10.2196/preprints.79421
Chen, X., Meng, Y., Chen, B., Liu, B., Zhang, L., García, C., Sareh, P., Xiao, Y., & Zhang, B. (2025) · doi:10.2196/preprints.82620
Clinical Trials and Patents Related to Anti-diabetic Properties of Algae
Esther Shoba, R., Ramachandran, D., & Angeline, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-95-0571-5_13
Algae to the Rescue: Unveiling the Potential Role of Neuroprotection in Diabetic Neuropathy
Kathirvel, M. (2025) · Springer eBooks · doi:10.1007/978-981-95-0571-5_7
Diabetes: Current Treatment and Its Management
Arularasu, M. V., Vinitha, P., & Nelaturi, P. (2025) · Springer eBooks · doi:10.1007/978-981-95-0571-5_2
Razzak, S., Bibi, S., Ahmed, S. T., Ali, M. S., Kanwal, U., Asif, L., Ateeque, S., & Nehal, A. (2025) · International Journal of Pharmacy & Integrated Health Sciences · doi:10.56536/ijpihs.v6i2.267
Dsouza, S. M., Venne, J., Shetty, S., & Brand, H. (2024) · Figshare · doi:10.6084/m9.figshare.26755675
Huthmacher, J. A. (2024) · Dokumentenrepositorium der RUB (Ruhr University Bochum) · doi:10.13154/294-12676
IMPROVING RISK PREDICTION AND TREATMENT DECISIONS USING AUXILIARY INFORMATION
Xie, W. (2024) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/pmxy-n574
Introduction to Precision Medicine and Personalized Therapies in Health and Diseases
Sarkar, M., & Borah, R. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-95-2104-3_1
Insulina inalável: desenvolvimento de dispositivo tecnológico
Matos, I. L. S. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Pedregoza, D. J. B., & Ganotise, R. O. O. (2025) · Research in Clinical Pharmacy · doi:10.59931/rcp.25.0013
Baran, H. I., Sahinoglu, N., & Cicek, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-07267-2_11
Roney, M., Gazali, A. M., Akter, S., & Aluwi, M. F. F. M. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00762-y
医療費増大の抑制における就労世代のマルチモビディティとメタボリックシンドローム対策の重要性 : 協会けんぽの健診・レセプトデータを活用した全国規模の分析 (本文)
ニシダ, ユ., Nishida, Y., & 西田, 優. (2023) · Institutional Repositories DataBase (IRDB)
Haruna, I., Sulemana, A.-R., Nakua, E. K., & Boateng, D. (2026) · BMC Public Health · doi:10.1186/s12889-026-27118-5
The Psychological and Social Impact of Diabetes on Patients’ Lives
Abubakar, M., Dahiya, R., Goyal, K., Kumar, N., Khan, I., Murti, K., & Rai, A. (2026) · Springer eBooks · doi:10.1007/978-981-95-8946-3_14
Srusti, H. G., Darshini, K., Poorvika, K. V., & Rout, B. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i5.7739
Sun, H., Shi, Z., Xia, Y., Bai, Y., Yu, M., Liu, R., & He, P. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-115755
Tewari, S., Pramanik, P., Patra, T., & Monika, M. K. (2026) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2026.v15.i3c.15891
Langa, B. (2025) · ResearchSpace (University of KwaZulu-Natal)
Zuhroidah, I., Sujarwadi, M., Toha, M., Asmaningrum, N., Prayoga, D. H., Laili, N. R., & Zahra, F. (2026) · Nursing and Health Sciences Journal (NHSJ) · doi:10.53713/nhsj.v6i2.668
Omar, M. H., Zakaria, Z. F., Nasruddin, W. N. W. M., & Mokhlis, M. (2026) · Malaysian Family Physician · doi:10.51866/oa.1119
Vajjiravelu, R., Kirtheka, P. S., Palani, B., Jayakodi, S., & Kirubakaran, D. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100719
Bose, A., Prochnow, T. M., Bergeron, C., Park, J.-H., Johannes, B. L., Sherman, L. D., Patterson, M. S., Merianos, A. L., & Smith, M. L. (2026) · Patient Preference and Adherence · doi:10.2147/ppa.s589075
Priyono, D., Jin, J. H., Kim, M.-S., Rahman, A. N. F., & Septiani, H. (2026) · Sehat Rakyat Jurnal Kesehatan Masyarakat · doi:10.54259/sehatrakyat.v5i2.7449
Emerging trends in immunogenetic research in type 2 diabetes mellitus (T2DM)
Vardhan, J., Sisodia, S., Mishra, P. S., Kumar, A., Jameel, M. R., & Ali, S. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33590-7.00007-1
Assuring AI safety for managing risk of myocardial infarction for patients with type 2 diabetes
Ozturk, B. (2026) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
da Silva, S. B., Limeira, R. D. F., Lucena, G. T. S., Pontes, A. R. L., & Coelho, C. S. H. M. (2026) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v12i6.27958
John, T., Mohanraj, S., Nawshin, T., Mehta, T. S., & Thirumalai, M. (2026) · JMIR Diabetes · doi:10.2196/81441
Fine-Tuning Open-Weight LLMs for Connected Health Management: A Case Study for Diabetes Management
Doğru, A. C., Canbolat, C., BAYRAKTAR, S., Jamil, M., & Kavak, A. (2026) · IEEE International Black Sea Conference on Communications and Networking · doi:10.1109/blackseacom69760.2026.11598306
Hung, K., Weng, H.-L., & Chen, I. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s624727
Goenka, H., & Mathur, R. (2026) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20263189
Wise, I. A., Berry, S. D., McKenzie, A., Steel, J. C., Edwards, K. P., Efron, N., Layton, C. J., & Ramlogan‐Steel, C. A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0358455
DEVELOPING A PERSONALIZED MEDICINE APPROACH FOR TREATING TYPE 2 DIABETES
VAISHNAV, V. A. D., PRADHAN, S., & Suyal, I. D. (2025) · TPM Testing, psychometrics, methodology in applied psychology
Use of a mobile application for maintaining self-care of an individual with type 2 diabetes
Gosak, L. (2025) · University of Maribor digital library (University of Maribor)
Murad, A., Imran, M., Noor, Z., Lal, L., Khan, A., Ahmad, Z., Khan, J., & Basit, A. (2026) · Annual Methodological Archive Research Review
Springer, M., Brix, L. M., Kovářová, V., Narayan, S., Harbich, D., Haworth, B., Mete, F. F., Suñer-Rubio, D., Stanciu, S., Aman, L., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102455
张鑫桐, Zhang, R., & Jiang, T. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70366
Fischer, A.-K., Sadler, A., Mathey, E., & Mühlbacher, A. C. (2026) · MDM Policy & Practice · doi:10.1177/23814683261493546
Das, R., Chettupalli, A. K., Bukke, S. P. N., Das, S., & Pathak, P. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261504896
Harada, K. S., Maeda, Y., Sekiguchi, D., Tamura, A., Hayashi, M., Ishikado, A., & Minami, M. (2026) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2026.200392
Ahmad, M., Albalawi, S. A., Aldawsari, N. A., Almehthel, M. S., & معاشي, ع. ا. (2026) · Cureus · doi:10.7759/cureus.119438
AI and Mobile Technologies for Population-Level Chronic Disease Prevention
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-9003-4
Lin, P., Desouza, C. V., Fu, A., Kristensen, N. R., Søgaard, S. B., & Liebl, A. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01928-7
Zhao, S., Li, H., Jing, X., Zhang, X., Li, R., Li, Y., Liu, C., Chen, J., Li, G., Zheng, W., et al. (2023) · doi:10.3389/fphar.2023.1210667.s002
Metadata
- Authors
- Williams, D. M., Jones, H., & Stephens, J. W.
- Affiliations
- Swansea Bay University Health Board (GB)
- Corresponding author
- Williams, David M
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-02
- Volume
- Volume 15
- Pages
- 281-295
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8824792
- OpenAlex
- W4210447482
- Cited by
- 121
- References
- 107
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 31 · 2023: 21 · 2022: 9
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, personalized medicine, glycemic control, diabetes pharmacotherapy, diabetes phenotypes, genetic biomarkers, comorbidities, hypoglycemia, medication adherence, patient satisfaction, quality of life, diabetes distress, weight management, treatment goals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.